

Indian Institute of Technology Delhi

Hauz Khas, New Delhi-110016

Notice Inviting Quotation

(e-Procurement Mode)

Open Tender Notice No: IITD/KHOS(SP-5232)/2026

Date: 16/01/2026

Subject: Empanelment of Diagnostic Testing Agency (DTA) for IIT Delhi Hospital.

Indian Institute of Technology Delhi (IIT Delhi) is a premier autonomous statutory organization under the Ministry of Education, Government of India and established through the “Institutes of Technology Act, 1961”, as amended by the “Institutes of Technology (Amendment) Act, 1963”. In recognition of its excellence in higher education and research, the Institute was declared an “Institute of Eminence” by the Government of India.

The multifarious medical needs of the students, staff and their family members are met by the Institute Hospital. The Hospital is headed by the Head, Hospital & Health Services) with a team of full-time Medical Officers, Visiting Specialists and Para Medical staff.

Indian Institute of Technology Delhi invites quotation through open tender from NABL accredited pathology labs in Delhi/NCR on the terms and conditions set out in this tender document.

The Expected volume of pathological tests/investigations to be conducted to the tune of Rs.1.5 Crore (approx.) as per the revised CGHS Rates.

Tender Documents may be downloaded from Central Public Procurement Portal <http://eprocure.gov.in/eprocure/app> and from the website of the IIT Delhi. Aspiring Bidders who have not enrolled / registered in e-procurement should enroll / register before participating through the website <http://eprocure.gov.in/eprocure/app>. The portal enrolment is free of charge.

The tender document consists of

- I. Tender Schedule
- II. Schedule A: Instructions for Online Bid Submission
- III. Schedule B: General Terms and Conditions
- IV. Annexures

Tender Schedule

Name of Organization	Indian Institute of Technology Delhi
Tender Type (Open/Limited/EOI/Auction/Single/Global)	Open
Tender Category (Services/Goods/works)	Services
Type/Form of Contract (Work/Supply/ Auction/ Service/ Buy/ Empanelment/ Sell)	Empanelment
Product Category (Civil Works/Electrical Works/Fleet Management/ Computer Systems)	Others
Source of Fund (Institute/Project)	Institute
Currency	Indian Rupee (INR)
Date of Issue/Publishing	16/01/2026 (17:00 Hrs)
Document Download/Sale Start Date	16/01/2026 (17:00 Hrs)
Document Download/Sale End Date	06/02/2026 (17:00 Hrs)
Last Date and Time for Uploading of Bids	06/02/2026 (17:00 Hrs)
Date and Time of Opening of Technical Bids	09/02/2026 (10:00 Hrs)
Date of Pre-bid Meeting	22/01/2025 (11:00 AM) Committee Room, IIT Hospital IIT Delhi, Hauz Khas-110016

No. of Covers (1/2/3/4)	02
Bid Validity days (180/120/90/60/30)	90 days (From last date of opening of tender)
Address for Communication	Mr. Manish Bharadwaj Assistant Registrar Hospital & Health Services, IIT Delhi, Hauz khas-110016
Contact No.	011-26596699
Email Address	arhealth@admin.iitd.ac.in

Schedule A

Instructions for Online Bid Submission

As per the directives of Department of Expenditure, this tender document has been published on the Central Public Procurement Portal (URL: <http://eprocure.gov.in/eprocure/app>). The bidders are required to submit soft copies of their bids electronically on the CPP Portal, using valid Digital Signature Certificates. The instructions given below are meant to assist the bidders in registering on the CPP Portal, prepare their bids in accordance with the requirements and submitting their bids online on the CPP Portal.

Registration

- Bidders are required to enroll on the e-Procurement module of the Central Public Procurement Portal (URL: <http://eprocure.gov.in/eprocure/app>) by clicking on the link “Online Bidder Enrollment” on the CPP Portal is free of charge.
- As part of the enrolment process, the bidders will be required to choose a unique username and assign a password for their accounts.
- Bidders are advised to register their valid email address and mobile numbers as part of the registration process. These would be used for any communication from the CPP Portal. Upon enrolment, the bidders will be required to register their valid Digital Signature Certificate (Class II or Class III Certificates with signing key usage) issued by any Certifying Authority recognized by CCA India (e.g. Sify / TCS / nCode / eMudhra etc.), with their profile.
- Only one valid DSC should be registered by a bidder. Please note that the bidders are responsible for ensuring that they do not lend their DSCs to others which may lead to misuse.
- Bidder then logs in to the site through the secured log-in by entering their user ID / password and the password of the DSC / e-Token.

Searching for tender Documents

- There is various search options built in the CPP Portal, to facilitate bidders to search active tenders by several parameters. These parameters could include Tender ID, organization name, location, date, value, etc. There is also an option of advanced search for tenders, wherein the bidders may combine a number of search parameters such as organization name, form of contract, location, date, other keywords etc. to search for a tender published on the CPP Portal.
- Once the bidders have selected the tenders they are interested in, they may download the required documents / tender schedules. These tenders can be moved to the respective ‘My Tenders’ folder. This would enable the CPP Portal to intimate the bidders through SMS / e-mail in case there is any corrigendum issued to the tender document.
- The bidder should make a note of the unique Tender ID assigned to each tender; in case they want to obtain any clarification / help from the Helpdesk.

Preparation of Bids

- Bidder should take into account any corrigendum published on the tender document before submitting their bids.
- Please go through the tender advertisement and the tender document carefully to understand the documents required to be submitted as part of the bid. Please note the number of covers in which the bid documents have to be submitted, the number of documents - including the names and content of each of the documents that need to be submitted. Any deviations from these may lead to rejection of the bid.
- Bidder, in advance, should get ready the bid documents to be submitted as indicated in the tender document / schedule and generally, they can be in PDF / XLS / RAR / DWF formats. Bid documents may be scanned with 100 dpi with black and white options.
- To avoid the time and effort required in uploading the same set of standard documents which are required to be submitted as a part of every bid, a provision of uploading such standard documents (e.g. PAN card copy, annual reports, auditor certificates etc.) has been provided to the bidders. Bidders can use “My Space” area available to them to upload such documents. These documents may be directly submitted from the “My Space” area while submitting a bid and need not be uploaded again and again. This will lead to a reduction in the time required for bid submission process.

Note: My Documents Space is only a repository given to the Bidders to ease the uploading process. If Bidder has uploaded his document in My document Space, this does not automatically ensure these documents being part of Technical Bid.

Submission of Bids

- Bidder should log into the site well in advance for bid submission so that they can upload the bid in time i.e. on or before the bid submission time. Bidder will be responsible for any delay due to other issues.
- The bidder has to digitally sign and upload the required bid documents one by one as indicated in the tender document.
- A standard BoQ format has been provided with the tender document to be filled by all the bidders. Bidders are requested to note that they should necessarily submit their financial bids in the format provided and no other format is acceptable. Bidders are required to download the BoQ file, open it and complete the white colored (unprotected) cells with their respective financial quotes and other details (such as name of the bidder). No other cells should be changed. Once the details have been completed, the bidder should save it and submit it online, without changing the filename. If the BoQ file is found to be modified by the bidder, the bid will be rejected.
- The server time (which is displayed on the bidders’ dashboard) will be considered as the standard time for referencing the deadlines for submission of the bids by the bidders, opening of bids etc. The bidders should follow this during bid submission.

- All the documents being submitted by the bidders would be encrypted using PKI encryption techniques to ensure the secrecy of the data. The data entered cannot be viewed by unauthorized people until the time of bid opening. The confidentiality of the bids is maintained using the secured Socket Layer 128-bit encryption technology. Data storage encryption of sensitive fields is done. Any bid document that is uploaded to symmetric encryption using buyers/bid opener's public keys. Overall, the uploaded documents become readable only after the tender opening by the authorized bid openers.
- Upon the successful and timely submission of bids (i.e. after clicking "Freeze Bid Submission" in the portal), the portal will give a successful bid submission message & a bid summary will be displayed with the bid no. and the date & time of submission of the bid with all other relevant details.
- The bid summary has to be printed and kept as an acknowledgement of the submission of the bid.
- The bid should be submitted in two bid systems i.e. Technical Bid & Financial Bid.

Technical Bid

The following documents are required to be submitted / uploaded in the technical bid:

- Compliance Sheet (Annexure-I)
- Basic Details (Annexure-II)
- List of Govt. Organization/Deptt. (Annexure-III)
- Declaration (Annexure-IV)
- PAN and GST certificate of the organization
- Details of annual turnover of the organization/company for the past three financial years (viz., 2024-25, 2023-24 and 2022-23). Documentary proof in the form of an audited statement of annual accounts/ITR is required to be submitted.
- Compliance of list of Test in Annexure-V
- List of Non-CGHS Test with MRP in Annexure-VI

Financial Bid

Bidders are requested to note that they should submit their financial bid in the BoQ format provided and no other format is acceptable (Sample format is given in Annexure-VII & VIII).

Amendment of Tender Document

Before the deadline for submission of tenders, IITD may modify the tender documents by issuing corrigendum / addendum. Such corrigendum/ addendum thus issued shall be part of the tender documents and shall be published online in e- Procurement portal. To give prospective Bidders reasonable time in which to take corrigendum/ addendum into account in preparing.

Assistance to Bidders

- Any queries relating to the tender document and the terms and conditions contained therein should be addressed to the Tender Inviting Authority for a tender or the relevant contact person indicated in the tender.
- Any queries relating to the process of online bid submission or queries relating to CPP Portal in general may be directed to the 24x7 CPP Portal Helpdesk. The contact number for the helpdesk is 1800 233 7315.

Schedule-B

General Terms and Conditions

1. Scope of Work

1.1 The DTA shall set up a collection center at IIT Hospital to collect the sample for the following tests/investigations (Detailed list of tests placed at Annexure-V).

- a. Clinical Chemistry
- b. Clinical Hematology
- c. Clinical Microbiology
- d. Microscopy/Parasitology
- e. Serology
- f. Cytogenetics
- g. Molecular Diagnostics

1.2 The Diagnostic Testing Agency (DTA) shall provide the agreed upon services only to IIT Delhi beneficiaries referred by medical officers or visiting specialists of IIT Hospital.

1.3 The beneficiaries and the corresponding services required are as under:

a) **Employees of the Institute**

Credit/cashless pathological tests and investigations shall be provided to serving and retired employees of the Institute and their dependents, strictly **on the basis of a valid referral form/slip issued by IIT Hospital**. The referral slip/form contains the patient's details, viz. name, age, sex, and medical ID. Bills for such investigations shall be raised directly to the Institute as per agreed terms and condition.

b) **Students of the Institute**

Students of the Institute shall also be eligible to avail pathological testing and investigation services. However, such services should be provided on a **cash payment basis** at the agreed rates. The responsibility for collection of cash shall rest solely with the Diagnostic Testing Agency (DTA), and the Institute shall not assume any financial liability or responsibility in this regard.

1.4 Sample Collection Timing

The tentative timing for the sample collection is as mentioned below. However, the timing may be changed or extended at the discretion of IIT Delhi with prior intimation.

- Working Days (Monday to Friday) - 08:00 am – 2:00 pm.
- Weekend/Holidays - 09:00 am – 2:00 pm.

In case of emergency, the DTA may be summoned by the Head, Hospital & Health Services to collect samples at any time of the day or he/she may extend the sample collection duration.

1.5 Turnaround time (TAT) between the collection of samples and reporting for routine test should be 6-8 hours, on the day of sample collected. In case of emergency sample report is expected within 2-3 hours, for cultures 48 hours to 7 days. Preliminary report may be demanded by the Head, Hospital & Health Services, in case of any emergency as early as possible.

1.6 The DTA would not outsource the Institute cases further to other centers under normal circumstances. If it is essential, prior intimation should be given to the Head, Hospital & Health Services, and the reliability of the test results would be the sole responsibility of the DTA empaneled. Payment in such cases would also be restricted to approved/agreed rates only.

- 1.7 In case the investigations/tests carried out by the DTA are not found to be meeting the standards of quality as per norms in medical practice, the DTA will bear any liability towards costs of retesting of fresh/original sample and Institute will not have any financial or legal liability for the same.
- 1.8 Any liability arising out of or due to any default or negligence in provision or performance of the diagnostic services shall be borne exclusively by the DTA, who shall alone be responsible for the defect in rendering such services.
- 1.9 While carrying out tests/diagnostic procedures of Institute beneficiaries, the DTA shall not ask the Institute beneficiaries to purchase consumables from outside.
- 1.10 The DTA should have facilities for computational reporting / e-reporting.

2. Time Period of Empanelment

The selected DTA will be empaneled for providing pathological investigation services initially for a period of two years extendable by one year at a time up to a maximum period of five years upon satisfactory performance at the discretion of IIT Delhi. Notwithstanding anything contained herein above, the Institute reserves the right to discontinue the services of DTA with one-month notice period in the event their services are evaluated as unsatisfactory at any time during the period, and the test results are not reliable or not trustworthy.

3. Support and Inputs to the Diagnostic Testing Agency

The Institute will provide the necessary space/room within the IIT Hospital premises for establishing a collection center, without charging any rent or fees.

4. Pre-qualification Criterion/Eligibility for Participation

- i. The DTA should be based in Delhi NCR.
- ii. Diagnostic Testing Agency should have at least **FIVE** its own NABL accredited lab in Delhi/NCR to carry out at least 70% of CGHS listed pathology tests/investigation (Supporting documents should be submitted).
- iii. The lab in which tests/investigation are to be performed should be within 10 Km of IIT Delhi and should meet the following criteria:
 1. Qualified staff – pathologist MD/DNB (path) MD/DNB (Microbiology)/MD Phd (Biochemistry), Lab Technician (DMLT)
 2. The DTA should be NABL Accredited (with valid certification) for more than 10 years, including Clinical biochemistry, Clinical pathology, Cyto pathology, Serology, Haematology, Histo-Pathology and Microbiology.
- iv. The DTA should have experience in Central / State Government Offices / Organization / Autonomous Body etc. in last five years.
- v. The DTA should have registration with the Delhi State Government, Department of Health. The DTA should have valid GST Number, PAN.
- vi. **The DTA shall agree to provide cashless facilities to IIT Delhi Beneficiaries against referral slip/job form at all its labs/centers in Delhi NCR.**
- vii. The DTA should have an Average annual turnover (through testing services only) of not less than Rs. 50.00 crore (Rupees Fifty crore only) for the last three consecutive years i.e. 2022-23, 2023-24 and 2024-25. (Annexure-II). The supportive documents (ITR Returns /CA audited Certifications) to be submitted with the technical bid.

- viii. The DTA should not have reported losses in the preceding three financial years. Profit and loss statement for the preceding 3 financial years to be submitted with the technical bid.
- ix. The DTA should not have been blacklisted / debarred by any State/Centre Government organizations or whose approval had been suspended or revoked partially or in full by Statutory Authority in last five years from the last date of submission of bids.
- x. Home Sample Collection facility in Delhi/NCR.

5. Payment Terms

The DTA shall raise bills to IIT Delhi on a weekly/fortnightly/monthly basis, as decided by mutual consent at the time of award of the contract/MOU/agreement. Billing during the entire contract period shall be strictly as per the rates quoted in the financial bid or as accepted by the DTA at the time of signing the MOU/agreement. IIT Delhi shall make the payment within 20 days of receipt of the invoice.

The invoice shall be accompanied by a list (hard copy and soft copy) of all investigations carried out during the period, with complete patient details. The DTA shall submit all corresponding referral slip/form collected from the patient along with the invoice for the purpose of verification. In case of any mismatch in patient details in the referral slip or non-submission of the referral slip, the payment may be deducted by IIT Delhi.

Note: The referred patient has to produce the medical booklet duly affixed with the attested photograph issued to him/her along-with Identity Card of the employee. The DTA staff will certify the identity of the employees/ their dependents/ students, from the Identity Card/ Medical Booklets before carrying out the Tests. Checking the cards/ medical booklets, their validity and checking of identity is the sole responsibility of the DTA. There will be no reimbursement/payment for the investigations/tests in case, where the patient is not concerned with IIT Delhi or the Test carried out was not recommended by the IIT medical officers.

6. Technical Evaluation Procedure

Evaluation will be carried out by the Purchase Finalization Committee (PFC), constituted by the Director, IIT Delhi. The bidder should meet the basic eligibility defined in pre-qualification Criteria / eligibility criterion. The bidder who fails to fulfill any of the stipulated eligibility criteria shall **NOT** be eligible for the purpose of evaluation

The bidder shall be evaluated on the following pre-defined parameters and will get the marks as mentioned in the respective (Please Refer the table below). **Bidders who score more than 75 marks will be declared as 'TECHNICALY QUALIFIED' and eligible for further process of evaluation i.e. Financial Evaluation.**

Parameter		Marks	Maximum Marks
1.	Experience of Agency in managing DTA services		
	Experience of less than 20 Years	05	15
	Experience of more than 20 years and less than 30 years	10	
	Experience of more than 30 years	15	
2.	Average Annual Turnover in the last three financial years i.e. 2022-23, 2023-24 and 24-25.		
	Above 50 Crore and less than or equal to 100 Crore per year	05	15
	Above 100 Crore and Less than or equal to 200 Crore per year	10	
	More than 200 Crore	15	
3.	No. of Central /State Govt. Organizations / Institutions / Autonomous Body / PSU etc., which has empaneled the bidder for the purpose of		

	carrying out pathology test/investigation.		
	Up to 10	05	15
	More than 10 and up to 25	10	
	More than 25	15	
4.	Number of NABL accredited labs in Delhi/NCR		
	up to 10	05	15
	up to 20	10	
	More than 20	15	
5	% of tests on CGHS list of lab tests, in scope of NABL of DTA		
	Up to 70%	05	15
	Up to 80%	10	
	Above 80%	15	
6	Presentation on Technical Capability before the committee. (Lab Visit may be conducted)	25	

7. Financial Evaluation

The bidder declared as “Technically Qualified” shall only be considered for the purpose of financial evaluation. The Sheet-1 of BOQ i.e. financial bid contains the price quoted in terms of discount offered by bidder on CGHS rates. More is the value of discount lesser will be the price for test/investigation. Therefore, the bidder quoted higher discount will be declared as L-1 bidder and eligible for the award of contract **(In case of tie with the discount rate quoted in Sheet-1, the bidder scoring more points in technical evaluation shall be declared as L-1 bidder and eligible for award of contract).**

The Sheet-2 of financial bid contains price quoted for non-CGHS test/investigations in terms of flat discount on MRP as defined by the bidder in Annexure-VI. The sheet -2 will NOT be considered for financial evaluation.

The sample format for Sheet-1 & Sheet-2 of BoQ is attached as Annexure-VII & Annexure-VIII for reference.

Note: Bidders are requested to note that they should submit their financial bid in the BoQ format on CPP portal only, no other means of submission is acceptable.

8. Award of Contract & Agreement

The IIT Delhi will award the Contract to the successful bidder declared as L-1, provided further that the bidder has been determined to be qualified to satisfactory perform the Contract. The selected bidder shall sign an agreement with IITD, which will be executed as per the provisions of the Stamp Act.

9. Performance Security

The L-1 bidder shall be required to submit/deposit Rs.5,00,000/- (Five Lakh) towards Performance Security in the form of irrevocable bank guarantee issued by any Indian Nationalized Bank within 21 days from the date of award of contract and before the initiation of contract, whichever is earlier. The performance security should be kept valid for a period of 60 days beyond the date of completion Contract. The account details are as below: (To be paid through RTGS/NEFT. IIT Delhi Bank details are as under:

Name of the Bank A/C : IITD Revenue Account
SBI A/C No. : 10773572622
Name of the Bank : State Bank of India, IIT Delhi, Hauz Khas, New Delhi 110016
IFSC Code : SBIN0001077

10. Disputes and Jurisdiction

Any legal disputes arising out of any breach of contract pertaining to this tender during the tendering process or during the policy period shall be settled in the court of competent jurisdiction located within the local limits of Delhi.

11. Important Instructions

- i. The bids are invited under two bid systems i.e. Technical Bid and Financial Bid, documents are to be uploaded in the CPPP portal as mentioned in the compliance sheet (Annexure-I).
- ii. All Bidders shall provide the required information accurately and enough as per details in Eligibility Criteria. The bidder should upload the copy of the technical bids and documents in the CPP portal and further documents as mentioned in the compliance sheet (Annexure-I) on or before the last date of submission of tender.
- iii. Blacklisted bidder in State / Central Govt. Departments, Central / State PSUs, Autonomous Organizations/ Boards etc., are not eligible to quote, if found such tenders will be rejected.
- iv. The IIT Delhi reserves the right to accept / reject any or all the tenders without assigning any reasons.
- v. Conditional tenders will not be accepted and are liable for rejection.
- vi. Bidders who meet the specified minimum qualifying criteria shall be eligible. Even though the Bidders meets the eligible criteria, they are subject to be disqualified if they have made misleading or false representations in the forms, statements and attachments submitted in proof of the qualification requirements.
- vii. Bidders are hereby informed that canvassing in any form for influencing the process of notification of award would result in disqualification of the Bidder.
- viii. IIT Delhi will reject a proposal / declare a firm ineligible for award if it determines that the bidder have engaged in corrupt or fraudulent practices.
- ix. IIT Delhi takes no responsibility for delays, loss or non-receipt of tender documents and reserve the right to reject any offer in part or full without assigning any reason thereof.
- x. IIT Delhi may at its discretion extend/ change the schedule of any activity and intimate the prospective bidders by notification through CPP Portal/IIT Delhi Website.
- xi. IIT Delhi reserves the right to accept or reject any bids or accept all bids either in part or in full or to split the order, or to annul the bidding process without assigning any reasons thereof.
- xii. The bid must be valid for 90 days from the date of opening of Technical Bids.
- xiii. Tax deductions at source – TDS and GST on TDS or any other TAX deduction at source shall be governed as per GOI prevailing rules.

ANNEXURE-I

(In Reference to DTA Empanelment Tender of IIT Delhi)

**<< Organization Letter Head >>
Compliance Sheet**

We _____ hereby certify that we have gone through all the T&C of the IIT Delhi tender for empanelment of DTA and we confirm that we fulfill all eligibility criteria as stated below to participate in the tender:

S.No	Details of Compliance as stated in the Eligibility Column	Compliance (Y/N)
1	The DTA should be based in Delhi NCR (Fill and upload the Basic Details in Annexure-II).	
2	Diagnostic Testing Agency should have at least FIVE its own NABL accredited lab in Delhi/NCR to carry out at least 70% of CGHS listed pathology tests/investigation (Supporting documents should be submitted in technical bid).	
3	The DTA should have registration with the Delhi State Government, Department of Health. valid GST No (PAN based), PAN No.	
4	The DTA shall agree to provide cashless facility to IIT Delhi Beneficiaries against referral slip/job form at all its labs/centers in Delhi NCR	
5	Diagnostic Testing Agency has a lab within 10 Km of IIT Delhi and meets following conditions: a) Qualified staff – pathologist MD/DNB (path) MD/DNB (Microbiology)/MD Phd (Biochemistry), Lab Technician (DMLT) b) The DTA should be NABL Accredited (with valid certification) for more than 10 years, including Clinical biochemistry, Clinical pathology, Cyto pathology, Serology, Haematology, Histo-Pathology and Microbiology Note: Certificates and copies of support documents with respect the above requirement shall be submitted along with the “Technical Bid”.	
6	The DTA should have an Average annual turnover of not less than Rs.50.00 crore (Rupees Fifty crore only) for the last three consecutive years i.e. 2022-23, 2023-24 and 2024-25. The Supportive (ITR Returns/CA Certifications) documents to be submitted with the technical bid.	
7	The DTA should have experience in Central / State Government Offices / Organization / Autonomous Body etc. in last five years.	
8	The DTA has not been blacklisted / debarred by any State/Centre Government organizations or whose approval had been suspended or revoked partially or in full by Statutory Authority in last five years from the last date of submission of bids. (Self-Declaration)	
9	The DTA has not been withdrawn from the list of DTA empaneled under CGHS Delhi, based on the recommendations of the Ethics Committee of Medical Council of India in last five years from the last date of submission of bids. (Self -Declaration)	
10	The DTA should not have reported losses in the preceding three financial years. Profit and loss statement for the preceding 3 financial years to be submitted with the technical bid	
11	Home Sample Collection Facility in Delhi/NCR	

Signature of the Bidder**Name :** _____**Designation :** _____**Organization :** _____**Contact No. :** _____

ANNEXURE-II

(In Reference to DTA Empanelment Tender of IIT Delhi)

<< Organization Letter Head >>

Basic Details

NAME & ADDRESS OF BIDDER			
1. Phone			
2. Fax			
3. E-mail			
4. Contact Person Name			
5. Mobile Number			
6. GST Number			
7. PAN			
8. Registration No. with State Govt., Deptt. of Health.			
9. Turnover in last three financial years (ITR Return or CA audited statement is to be submitted in technical bid as a supporting document)	FY: 2022-23	FY: 2023-24	FY: 2024-25

Signature of the Bidder**Name :** _____**Designation :** _____**Organization :** _____**Contact No. :** _____

List of Central/State Government Organizations / Departments / Autonomous Body to whom the Bidder has provided services as a DTA in last five years		
Name of the organization	Name of Contact Person	Contact No.

Signature of the Bidder

Name : _____

Designation : _____

Organization : _____

Contact No. : _____

**<< Organization Letter Head >>
DECLARATION SHEET**

We_____hereby certify that all the information and data furnished by our organization with regard to this tender specification are true and complete to the best of our knowledge. I have gone through the specifications, conditions and stipulations in detail and agree to comply with the requirements and intent of specification.

We Agree to provide cashless facility to all the eligible beneficiaries of IIT Delhi in all of our labs/centers in Delhi/NCR.

We certify that our organization meets all the conditions of eligibility criteria laid down in this tender document. We have not been blacklisted by any Govt./PSU in last 5 years.

We have not been withdrawn from the list of DTA empaneled under CGHS Delhi – especially on the basis of the recommendations of Ethics Committee of Medical Council of India in last five years from the date of last date of submission of bids.

The prices quoted in the financial bids are subsidized due to academic discount given to IIT Delhi.

Signature of the Bidder

Name : _____

Designation : _____

Organization : _____

Contact No. : _____

Annexure-V
(In Reference to DTA Empanelment Tender of IIT Delhi)

List of Tests

Sr. No	CGHS Code	CGHS TREATMENT PROCEDURE/INVESTIGATION LIST	Compliance (Y/N)
1	LB001	Urine Routine- pH, Specific Gravity, Sugar, Protein and Microscopy	
2	LB002	Urine Microalbumin	
3	LB003	Stool Routine and Microscopy	
4	LB004	Stool for Occult Blood	
5	LB005	Post Coital Smear Examination	
6	LB006	Semen Analysis (Automated/Manual)	
7	LB007	Haemoglobin (Hb)	
8	LB008	Total Leucocytic Count (TLC)	
9	LB009	Differential Leucocytic Count (DLC)	
10	LB010	Erythrocyte Sedimentation Rate (ESR)	
11	LB011	Total Red Cell count with MCV,MCH,MCHC,DRW	
12	LB012	Complete Haemogram/CBC, Hb, RBC Count and Indices, TLC, DLC, Platelet, ESR, Peripheral Smear Examination)	
13	LB013	Platelet Count	
14	LB014	Reticulocyte Count	
15	LB015	Absolute Eosinophil Count (AEC)	
16	LB016	Packed Cell Volume (PCV)	
17	LB017	Peripheral Smear Examination	
18	LB018	Smear for Malaria/Filaria Parasite	
19	LB019	Bleeding Time	
20	LB020	Clotting Time	
21	LB021	Osmotic Fragility Test	
22	LB022	Bone Marrow Smear Examination	
23	LB023	Bone Marrow Smear Examination with Iron Stain	
24	LB024	Bone Marrow Smear Examination and Cytochemistry	
25	LB025	Activated Partial Thromboplastin Time (APTT)	
26	LB026	Rapid Test for Malaria (Card Test)/QBC Malaria Test	
27	LB027	Bleeding Disorder Panel- PT, APTT, Thrombin Time Fibrinogen, D-Dimer/ Fibrinogen Degradation Products (FDP)	
28	LB028	Factor Assays-Factor VIII	
29	LB029	Factor Assays-Factor IX	
30	LB030	Platelet Function Tests	
31	LB031	Tests for Hypercoagulable States- Protein C, Protein S, Antithrombin	
32	LB032	Tests for Lupus Anticoagulant	
33	LB033	Tests for Antiphospholipid Antibody IgG, IgM (for Cardiolipin and B2 Glycoprotein 1)	

34	LB034	Thalassemia Studies (Red Cell Indices and Hb HPLC)	
35	LB035	Tests for Sickling / Hb HPLC)	
36	LB036	Blood Group & Rh Type	
37	LB037	Cross Match	
38	LB038	Coomb's Test - Direct	
39	LB039	Coomb's Test - Indirect	
40	LB040	3 Cell Panel- Antibody Screening for Pregnant Female	
41	LB041	11 Cells Panel for Antibody Identification	
42	LB042	Hepatitis B Surface Antigen (HBsAg)	
43	LB043	Hepatitis C Virus (HCV)	
44	LB044	Human Immunodeficiency Virus- HIV I and II	
45	LB045	Venereal Disease Research Laboratory Test (VDRL)	
46	LB046	Rh Antibody Titre	
47	LB047	Platelet Concentrate Test	
48	LB048	Routine - H & E	
49	LB049	Special Stain	
50	LB050	Histopathology Examination (HPE) - Frozen Section	
51	LB051	Histopathology Examination (HPE) - Paraffin Section	
52	LB052	Pap Smear	
53	LB053	Body Fluid for Malignant cells	
54	LB054	Paroxysmal Nocturnal Haemoglobinuria (PNH) Panel- CD55, CD59	
55	LB055	Blood Glucose Random / Blood Glucose Fasting /Blood Glucose PP	
56	LB056	24 Hrs Urine for Proteins, Sodium, Creatinine	
57	LB057	Blood Urea Nitrogen (BUN) / Urea	
58	LB058	Serum Creatinine	
59	LB059	Urine Bile Pigment and Salt	
60	LB060	Urine Urobilinogen	
61	LB061	Urine Ketones	
62	LB062	Urine Occult Blood	
63	LB063	Urine Total Proteins	
64	LB064	Rheumatoid Factor / Rh Factor Test	
65	LB065	Bence Jones Protein	
66	LB066	Serum Uric Acid	
67	LB067	Serum Bilirubin total & direct	
68	LB068	Serum Iron	
69	LB069	C-Reactive Protein (CRP)	
70	LB070	C-Reactive Protein (CRP) Quantitative	
71	LB071	Body Fluid (CSF/Ascitic Fluid etc.) Sugar, Protein etc.	
72	LB072	Albumin	
73	LB073	Creatinine Clearance	
74	LB074	Serum Cholesterol	
75	LB075	Total Iron Binding Capacity (TIBC)	
76	LB076	Glucose (Fasting & PP)	
77	LB077	Serum Calcium –Total	
78	LB078	Serum Calcium – Ionic	

79	LB079	Serum Phosphorus	
80	LB080	Total Protein Albumin/Globulin Ratio (A/G Ratio)	
81	LB081	Immunoglobulin G (IgG)	
82	LB082	Immunoglobulin M(IgM)	
83	LB083	Immunoglobulin A(IgA)	
84	LB084	Antinuclear Antibody (ANA)	
85	LB085	Anti-double stranded DNA (anti-dsDNA)	
86	LB086	Serum Glutamic Pyruvic Transaminase (SGPT) / Alanine Aminotransferase (ALT)	
87	LB087	Serum Glutamic Oxaloacetic Transaminase (SGOT) /Aspartate Aminotransferase (AST)	
88	LB088	Serum Amylase	
89	LB089	Serum Lipase	
90	LB090	Serum Lactate	
91	LB091	Serum Magnesium	
92	LB092	Serum Sodium	
93	LB093	Serum Potassium	
94	LB094	Chloride	
95	LB095	Serum Bicarbonate	
96	LB096	Serum Ammonia	
97	LB097	Anaemia Profile (Hb, Serum Iron, TIBC, Ferritin, Transferrin Saturation,Stool Occult Blood, CBC, Reticulocyte Count)	
98	LB098	Serum Testosterone	
99	LB099	Imprint Smear from Endoscopy	
100	LB100	Triglycerides	
101	LB101	Glucose Tolerance Test (GTT)	
102	LB102	Triple Marker Test (AFP,HCG,UE3)	
103	LB103	Creatine Phosphokinase (CPK)/Creatine Kinase (CK)	
104	LB104	Foetal Haemoglobin (HbF)	
105	LB105	Prothrombin Time (PT)/ International normalized ratio (INR)	
106	LB106	Lactate dehydrogenase (LDH)	
107	LB107	Alkaline Phosphatase	
108	LB108	Acid Phosphatase	
109	LB109	CPK MB/CK MB	
110	LB110	CK MB Mass/CPK MB Mass	
111	LB111	Troponin I	
112	LB112	Troponin T	
113	LB113	Glucose-6-Phosphate Dehydrogenase (G6PD)	
114	LB114	Lithium	
115	LB115	Dilantin (Phenytoin)	
116	LB116	Carbamazepine.	
117	LB117	Cyclosporine	
118	LB118	Valproic acid.	
119	LB119	Blood gas analysis / Arterial Blood Gas (ABG)	
120	LB120	Blood gas analysis / Arterial Blood Gas (ABG) with	

		electrolytes	
121	LB121	Urine Pregnancy Test(UPT)	
122	LB122	Glycosylated Haemoglobin (HbA1c)	
123	LB123	Kidney Function Test (KFT)- (Sr.Creatinine,Blood Urea,BUN,Sr.Uric Acid,Sr.Sodium,Sr.Potassium,Urine R/E)	
124	LB124	Liver Function Test (LFT)	
125	LB125	Lipid Profile (Total cholesterol ,Triglycerides, LDL, HDL,VLDL)	
126	LB126	Serum Ferritin	
127	LB127	Vitamin B12 Assay.	
128	LB128	Folic Acid Assay.	
129	LB129	Extended Lipid Profile. (Total cholesterol, LDL,HDL, Triglycerides Apo A1, Apo B,Lp (a))	
130	LB130	Apolipoprotein A1 (ApoA1)	
131	LB131	Apolipoprotein B (Apo B)	
132	LB132	Lipoprotein A / Lp A	
133	LB133	CD 3,4 and 8 Counts	
134	LB134	CD 3,4 and 8 Percentage	
135	LB135	Low Density Lipoprotein (LDL)	
136	LB136	Homocysteine	
137	LB137	Serum Electrophoresis	
138	LB138	Fibrinogen	
139	LB139	Gamma-Glutamyl Transpeptidase (GGTP)	
140	LB140	Fructosamine	
141	LB141	Beta 2 microglobulin (B2M) /β2 microglobulin	
142	LB142	Prostate Specific Antigen (PSA)- Total	
143	LB143	Prostate-Specific Antigen (PSA) - Free	
144	LB144	Alpha Fetoprotein (AFP)	
145	LB145	Human Chorionic Gonadotropin (HCG)/ Beta HCG	
146	LB146	Cancer Antigen 125 (CA 125)	
147	LB147	Cancer Antigen 19.9 (CA 19.9)	
148	LB148	Cancer Antigen 15.3 (CA 15.3)	
149	LB149	Vanillylmandelic Acid (VMA)	
150	LB150	Calcitonin	
151	LB151	Carcinoembryonic Antigen (CEA)	
152	LB152	Direct Immunofluorescence (Skin and Kidney Disease etc)	
153	LB153	Indirect (anti ds DNA Anti Smith ANCA)	
154	LB154	Calcidiol / 25-hydroxycholecalciferol / Vitamin D3 assay (Vit D3)	
155	LB155	Serum Protein electrophoresis with immunofixation electrophoresis (IFE)	
156	LB156	Anti-Cyclic Citrullinated Peptide (Anti CCP)	
157	LB157	Anti-tissue Transglutaminase antibody (Anti TTG Antibody) / Tissue Transglutaminase IgA (tTg-IgA)	
158	LB158	Serum Erythropoietin	

159	LB159	Adrenocorticotrophic Hormone (ACTH)	
160	LB160	T3, T4, TSH -Thyroid Function Test (TFT)	
161	LB161	Thyroid stimulating hormone (TSH)	
162	LB162	Luteinizing hormone (LH)	
163	LB163	Follicle stimulating hormone (FSH)	
164	LB164	Prolactin	
165	LB165	Cortisol	
166	LB166	PTH(Parathormone)	
167	LB167	C-Peptide (Connecting Peptide)	
168	LB168	Insulin	
169	LB169	Progesterone	
170	LB170	17 Hydroxyprogesterone (17 OH Progesterone)	
171	LB171	Dehydroepiandrosterone sulfate (DHEAS)	
172	LB172	Androstenedione	
173	LB173	Growth Hormone	
174	LB174	Thyroid peroxidase antibody (TPO)	
175	LB175	Thyroglobulin.	
176	LB176	Hydatid Serology	
177	LB177	Anti Sperm Antibodies.	
178	LB178	Hepatitis B Virus (HBV) DNA Qualitative	
179	LB179	Hepatitis B Virus (HBV) DNA Quantitative.	
180	LB180	Hepatitis C Virus (HCV) RNA Qualitative.	
181	LB181	Human papillomavirus (HPV) Serology	
182	LB182	Rota Virus serology	
183	LB183	Mantoux Test	
184	LB184	ADA(Adenosine deaminase)	
185	LB185	GeneXpert Test (Tuberculosis)	
186	LB186	QuantiFERON TB Gold	
187	LB187	PCR for Tuberculosis (TB)	
188	LB188	PCR for Human immunodeficiency virus (HIV)	
189	LB189	Chlamydia antigen	
190	LB190	Chlamydia antibody	
191	LB191	Brucella serology	
192	LB192	Influenza A serology	
193	LB193	Acetylcholine receptor (AChR) antibody titre	
194	LB194	Anti muscle specific receptor tyrosine kinase (Anti MuSK) antibody titre	
195	LB195	Serum Copper	
196	LB196	Serum Ceruloplasmin	
197	LB197	Urinary copper	
198	LB198	Serum phenobarbitone level	
199	LB199	Coagulation profile	
200	LB200	D-Dimer	
201	LB201	CSF/Any Body Fluid for Basic studies including cell count, protein, sugar, gram stain, India Ink preparation and smear for AFB	
202	LB202	PCR for Herpes simplex	
203	LB203	Bacterial culture and sensitivity - Aerobic	

204	LB204	Bacterial culture and sensitivity - Anaerobic	
205	LB205	Mycobacterial culture and sensitivity	
206	LB206	Fungal culture	
207	LB207	Anti measles antibody titre (with serum antibody titre)	
208	LB208	Viral culture	
209	LB209	Antibody titre (Herpes simplex, cytomegalovirus, flavivirus, zoster varicella virus)	
210	LB210	Oligoclonal bands (OCBs)	
211	LB211	Myelin basic protein (MBP)	
212	LB212	Cryptococcal antigen	
213	LB213	D Xylose test	
214	LB214	Faecal / Faecal fat test/ faecal chymotrypsin/ faecal elastase	
215	LB215	H pylori serology for Coeliac disease /Celiac disease	
216	LB216	HBV genotyping	
217	LB217	HCV genotyping	
218	LB218	Urinary Vanillylmandelic Acid (VMA)	
219	LB219	Urinary metanephrine/Normetanephrine	
220	LB220	Urinary free catecholamine	
221	LB221	Serum aldosterone	
222	LB222	24 Hr urinary aldosterone	
223	LB223	Plasma renin activity	
224	LB224	Serum aldosterone/renin ratio	
225	LB225	Osmolality urine	
226	LB226	Osmolality serum	
227	LB227	Urinary sodium	
228	LB228	Urinary Chloride	
229	LB229	Urinary potassium	
230	LB230	Urinary calcium	
231	LB231	Thyroid binding globulin	
232	LB232	24-hour urinary free cortisol	
233	LB233	Islet cell antibody	
234	LB234	Glutamic Acid Decarboxylase Autoantibodies test (GAD antibodies)	
235	LB235	Insulin associated antibody	
236	LB236	Insulin-like growth factor-1 (IGF-1)	
237	LB237	Insulin-like growth factor binding protein 3 (IGF- BP3)	
238	LB238	Sex hormone binding globulin	
239	LB239	Estradiol (E2)	
240	LB240	Thyroglobulin antibody	
241	LB241	Kappa Lambda Light Chains, Free, Serum/ Serum free light chains (SFLC)	
242	LB242	Serum IgE Level	
243	LB243	N-terminal pro BNP (NT-pro BNP / Brain natriuretic peptide (BNP)	
244	LB244	HCV RNA Quantitative	
245	LB245	Tacrolimus Level	

246	LB246	Protein Creatinine Ratio (PCR), Urine / Albumin Creatinine Ratio (ACR), Urine	
247	LB247	HLA B27 (PCR)	
248	LB248	Procalcitonin	
249	LB249	TORCH Test	
250	LB250	Anti –Smooth Muscle Antibody Test (ASMA)	
251	LB251	C ANCA-IFA	
252	LB252	P ANCA-IFA	
253	LB253	Angiotensin converting enzyme (ACE)	
254	LB254	Extractable Nuclear Antigens (ENA) - Quantitative	
255	LB255	Chromogranin A	
256	LB256	Faecal calprotectin	
257	LB257	C3-COMPLEMENT	
258	LB258	C4-COMPLEMENT	
259	LB259	H1N1 (RT-PCR)	
260	LB260	Anti HEV IgM	
261	LB261	Anti HAV IgM	
262	LB262	HBsAg Quantitative	
263	LB263	Typhidot IgM	
264	LB264	Hepatitis B Core Antibody (HBcAb) Level (Hepatitis B Core IgM Antibody)	
265	LB265	Hepatitis B surface antibody (anti HBs)	
266	LB266	Free Triiodothyronine (FT3)	
267	LB267	Free Thyroxine (FT4)	
268	LB268	Widal Test	
269	LB269	Dengue NS1 Ag	
270	LB270	Dengue IgM and Ig G	
271	LB271	Interleukin 6 (IL 6)	
272	LB272	Covid Antibody Test	
273	LB273	Cryoglobulins	
274	LB274	Cytogenetics	
275	LB275	Plasma Free Normetanephrine	
276	LB276	Plasma Metanephrines	
277	LB277	PLA2 receptor antibody quantitative	
278	LB278	Allergic Bronchopulmonary Aspergillosis (ABPA) Panel	
279	LB279	Allergy Food Screening Panel	
280	LB280	AMA (Anti Mitochondrial Antibody)	
281	LB281	AMH (Anti- Mullerian Hormone)	
282	LB282	ANA BLOT	
283	LB283	ANA Profile	
284	LB284	Anti GBM (Glomerular Basement Membrane) Antibody	
285	LB285	Anti LKM (Liver Kidney Microsome) Ab	
286	LB286	Anti Parietal Cell Antibodies	
287	LB287	Anti Intrinsic Factor Antibodies	
288	LB288	ASO Titre /ASLO Titre	
289	LB289	Aspergillus Fumigatus Specific IgE	
290	LB290	Autoimmune Encephalitis Panel	

291	LB291	Autoimmune Hepatitis Profile	
292	LB292	Beta-D-Glucan Assay	
293	LB293	C1 Esterase inhibitor (Quantitative)	
294	LB294	CMV Quantitative (Viral load) Test	
295	LB295	Double Marker (Beta-hCG,PAPP-A)	
296	LB296	Quadruple test (AFP,HCG,UE3,Inhibin A)	
297	LB297	HBeAb (Hepatitis B envelope Antibody)	
298	LB298	HBeAg (Hepatitis B envelope Antigen)	
299	LB299	HIAA 24 Hours Urinary	
300	LB300	HIV Viral Load by PCR	
301	LB301	HSV 1 & 2 IgG	
302	LB302	Hypersensitive Pneumonitis Panel	
303	LB303	IgG4	
304	LB304	Inhibin A	
305	LB305	Inhibin B	
306	LB306	Scrub Typhus IgM	
307	LB307	Interferon Gamma Release Assay (IGRA)	
308	LB308	KOH Mount	
309	LB309	Serum AMA M2 (IFA Method)	
310	LB310	Serum Gastrin	
311	LB311	Serum Haptoglobin Levels	
312	LB312	Skin Prick Test for Allergy	
313	LB313	Myositis Profile (Up to 16 Antigens)	
314	LB314	Paraneoplastic Panel	
315	LB315	TSH Receptor Antibody	
316	LB316	Anti-Nuclear Antibodies - IFA	
317	LB317	Autoimmune Liver Diseases Profile	
318	LB318	Citrate Urine 24 Hour	
319	LB319	Comprehensive Allergy Panel	
320	LB320	Comprehensive Myeloma Protein Panel	
321	LB321	DCP (DES Gamma-Carboxy- Prothrombin)	
322	LB322	Desmoglein (DSG) 1 And 3 Antibody	
323	LB323	Galactomannan	
324	LB324	SCL 70 Antibody	
325	LB325	Serum Chromogranin A	
326	LB326	SSA- Antibody Ro Serum Test	
327	LB327	SSB- Antibody La Serum Test	
328	LB328	Stool for Clostridium difficile Toxin	
329	LB329	TPHA	
330	LB330	UGT1A1 Gene Analysis	
331	LB331	Urine For Myoglobin	
332	LB332	Leptospira Ig M	
333	LB333	Chikungunya Ig M	
334	LB334	Weil Felix Agglutination Test	
335	LB335	Continuous Glucose Monitoring for 2 Weeks	
336	BY001	Skin Biopsy	
337	BY002	Punch/Wedge biopsy	

338	BY003	Excision Biopsy of Ulcers	
339	BY004	Excision Biopsy of Superficial Lumps	
340	BY005	Incision Biopsy of Growths/Ulcers	
341	BY006	Bone Marrow Aspiration and Biopsy	
342	BY007	Scalene Node Biopsy	
343	BY008	Liver Biopsy	
344	BY009	Muscle Biopsy	
345	BY010	Trucut Needle Biopsy- (excluding the cost of Needle/Biopsy Gun if used)	
346	CA001	A, B, DR Molecular Typing PCR - SSP	
347	CA002	ABL Kinase Domain Mutation for Chronic Myeloid leukemia (TKI Resistance, Imatinib Resistance	
348	CA003	ABL Kinase Domain Mutation for Ph Positive Acute Lymphoblastic leukemia (TKI Resistance, I	
349	CA004	Acute Leukemia karyotyping	
350	CA005	Acute Leukemia mutation detection (per gene)ASXL1 /c-KIT/DNMT3A/ IDH1 and IDH2 /K RAS and N RAS mutation detection	
351	CA006	Acute Leukemia RUNX1 mutation detection	
352	CA007	Acute Leukemia TET2 mutation detection	
353	CA008	Acute Leukemia TP53 mutation detection	
354	CA009	Acute Lymphoblastic leukemia karyotyping	
355	CA010	Acute Lymphoblastic Leukemia Mutation Detection	
356	CA011	Acute Lymphoblastic Leukemia Transcript Identification	
357	CA012	Acute Myeloid Leukemia (AML) Panel	
358	CA013	ALK -1	
359	CA014	ALK rearrangement: 2p23	
360	CA015	B-cell Acute Lymphoblastic Leukemia (B-ALL) Panel	
361	CA016	BCL3 rearrangement 19q13.3 / BCL6 rearrangement: 3q27	
362	CA017	BCOR alteration	
363	CA018	BCR/ABL (Ph) duplication, trisomy 8, trisomy 21, TP53 deletion	
364	CA019	BCR/ABL Ph: t(9;22)	
365	CA020	BCR-ABL by PCR-Quantitative	
366	CA021	BRAF	
367	CA022	BRCA1 & BRCA2	
368	CA023	C3d Single Allele Antibody for HLA Class I (C3dLSA Class I) /C3d Single Allele Antibody for HLA Class II (C3dLSA Class II)	
369	CA024	CAN ASSIST	
370	CA025	CCND1/IgH: t(11;14)	
371	CA026	CD 19 and CD 20	
372	CA027	Cell line karyotyping	
373	CA028	Chimerism Analysis	
374	CA029	Chromosomal breakage (fragility) studies in Fanconi's Anemia/Aplastic Anemia	
375	CA030	Chronic Lymphocytic Leukemia (CLL) Panel	
376	CA031	Chronic Lymphocytic Leukemia Comprehensive Mutation Profile (IGVH Gene Mutation & Usage, T	
377	CA032	Chronic Lymphocytic Leukemia IGVH Mutation Detection	

378	CA033	Chronic Lymphoproliferative disorder IGVH Mutation Detection	
379	CA034	Chronic Lymphoproliferative disorder NOTCH1 mutation / NOTCH2 mutation	
380	CA035	Chronic Lymphoproliferative disorder SF3B1 mutation	
381	CA036	Chronic Lymphoproliferative disorder TP53 mutation	
382	CA037	CLINICAL EXOME SEQUENCING	
383	CA038	CLL PANEL FISH	
384	CA039	CML Blast Crisis karyotyping	
385	CA040	Combined High Sensitivity JAK2 V617F and Exon12 Mutation Detection	
386	CA041	Comprehensive Molecular Testing	
387	CA042	Comprehensive Next Generation sequencing assay for Hematolymphoid malignancies	
388	CA043	Constitutional karyotyping	
389	CA044	Custom Sequencing Assay	
390	CA045	DICER1 Mutation	
391	CA046	Donor Specific Antibodies (DSA)	
392	CA047	EGFR Mutation DETECTION	
393	CA048	EGFR Resistance Mutation (T790m Mutation Analysis)	
394	CA049	ER PR Her2 Neu	
395	CA050	ER/PR/Her2neu, Ki67	
396	CA051	Extended Immune subset for Post Allogenic Stem Cell Transplant Monitoring	
397	CA052	Factor V Leiden Mutation Detection	
398	CA053	FISH for 1p33/TAL1 deletion	
399	CA054	FISH FOR HER2 Neu	
400	CA055	FISH for t(10;11)(p12;q14)/MLLT10(AF10)/PICALM	
401	CA056	FISH for t(11;19)(q23;p13.1)/KMT2A/ELL	
402	CA057	FISH for t(5;11)(q35;p15.5) NUP98/NSD1	
403	CA058	FISH for t(6;14)(p21;q32) IGH/CCND3	
404	CA059	FISH on Bone marrow Smear(1 marker)	
405	CA060	FISH on bone marrow smear(2 markers)	
406	CA061	FISH on FFPE - Block /Slide (2 markers)	
407	CA062	FISH PANEL FOR MYELOMA	
408	CA063	FISH Test for C19MC amplification	
409	CA064	FISH test for CDKN2A	
410	CA065	FISH test for CEN 10 loss - on Tissue	
411	CA066	FISH test for ETV6 break-apart analysis - On Tissue	
412	CA067	FISH test for MAML2 break-apart analysis - On Tissue	
413	CA068	Fluorescent PCR + fragment length analysis per Amplicon	
414	CA069	GeneCORE Somatic 161 Gene Panel (NGS)	
415	CA070	Hairy Cell Leukemia Mutation (BRAF V600E) Detection	
416	CA071	Hematolymphoid Malignancy At Diagnosis- Cancer Cytogenetics Testing	
417	CA072	Hematolymphoid Malignancy Follow-up- Cancer Cytogenetics Testing	
418	CA073	Hereditary Cancer Panel	
419	CA074	High Sensitivity JAK2 Mutation Detection (V617F)	

420	CA075	Histone Mutation Detection Assay	
421	CA076	HLA C, DQB Molecular Typing PCR - SSP	
422	CA077	HLA Disease Association Next Generation Sequencing HLA-A/B/DRB1/G	
423	CA078	HLA Disease Association Sequence based Typing HLA A/B/DRB1	
424	CA079	HLA Drug Hypersensitivity Next Generation Sequencing HLA-A/B/DRB1 HLA-A/B/DRB1/G	
425	CA080	HLA Drug Hypersensitivity Typing HLA-A/B/DRB1	
426	CA081	HLA Loss Chimerism	
427	CA082	HLA-A, B, C, DRB1, DQB1, DPB1 (Sequence Based Typing - SBT)	
428	CA083	HLA-A, B, DRB1 (Sequence Based Typing - SBT)	
429	CA084	HLA-A, B, DRB1(Sequence Specific Oligonucleotide - SSO)	
430	CA085	HLA-C, DQB1(Sequence Specific Oligonucleotide - SSO)	
431	CA086	HRR Gene Test	
432	CA087	IGH Characterization IGH/CCND1:t(11;14), IGH/BCL2:t(14;18),BCL6(3q27), MYC(8q24) (4markers	
433	CA088	IgH/BCL2 :t(14;18)	
434	CA089	IGHV Gene Mutation	
435	CA090	Interphase FISH test for Chr. 1 copy number variations	
436	CA091	IRFA/DUSP22 gene rearrangement by FISH	
437	CA092	JAK2 Exon 12 Mutation Detection	
438	CA093	JAK2V617 MUTATION, WITH REFLEX TO JAK2 EX-12,CALR EX-9 MUTATION AND MPL W515, S505 MUTATION	
439	CA094	KI67	
440	CA095	KIR Typing	
441	CA096	KMT2A Characterization for AML	
442	CA097	KMT2A Characterization for B-ALL	
443	CA098	KRAS + NRAS + BRAF + Mutation Profile	
444	CA099	Lineage specific Chimerism - B Cell, T Cell and NK Cells	
445	CA100	Liquid Biopsy (Onco)	
446	CA101	Lung Basic Panel By NGS	
447	CA102	Lymphoma Panel	
448	CA103	Lymphoplasmacytic Leukemia / Waldenstroms Macroglobulinemia Mutation (MYD88 L265P) Detection	
449	CA104	MDS Panel	
450	CA105	MECOM (EVI1) rearrangement: inv(3)(q21.3q26.2)/t(3;3)	
451	CA106	MGMT PCR	
452	CA107	Miscellaneous Profile I(1 marker)	
453	CA108	Miscellaneous profile II(2 markers)	
454	CA109	MLPA per gene	
455	CA110	Monosomy 5/deletion 5q	
456	CA111	Monosomy 7/deletion 7q	
457	CA112	MPN (Myelo Proliferative Neoplasm)PANEL	
458	CA113	MSI (Micro Satellite Instability) and MMR (Mis Match Repair)	
459	CA114	Multigene NGS Germline Panel	

460	CA115	Multiple Myeloma (MM) Panel	
461	CA116	Multiple Myeloma High Risk Markers (4 Markers)	
462	CA117	Multiple Myeloma Screening Panel	
463	CA118	MYD88 L265 Mutation Detection Test	
464	CA119	Myelodysplastic Syndromes karyotyping	
465	CA120	Next generation RNA sequencing assay for Chimeric Transcript in Hematolymphod malignancies	
466	CA121	Next Generation sequencing assay for Minimal residual disease(MRD) for NPM mutated AML	
467	CA122	NGS HLA Typing	
468	CA123	NGS Platform-extended Panel >50 gene	
469	CA124	NGS Platform-limited Panel(10 Genes)	
470	CA125	NRAS (Neuroblastoma RAS) Gene	
471	CA126	Panel Reactive Antibodies (PRA) class I	
472	CA127	Panel Reactive Antibodies (PRA) class II	
473	CA128	PCR + Sanger Sequencing per Amplicon	
474	CA129	PDGFRA (4q12), PDGFRB (5q33), FGFR1 (8p11.2) rearrangement	
475	CA130	PDGFRA rearrangement: 4q12	
476	CA131	PDGFRB rearrangement: 5q33	
477	CA132	PDL 1	
478	CA133	PDL-1-28-8 (FDA Approved)	
479	CA134	Ph: t(9;22) karyotyping	
480	CA135	Ph-like ALL Panel (4 Markers)	
481	CA136	PIK3CA GENE MUTATION	
482	CA137	PIK3CA Mutation Testing	
483	CA138	Ploidy analysis	
484	CA139	PML-RARA t(15;17), variants	
485	CA140	PRA Screen	
486	CA141	PTPRT: Deletion 20q	
487	CA142	RARA Variant - ZBTB16 / RARA : t(11;17) (1 marker)	
488	CA143	RHOA Mutation Detection Assay	
489	CA144	ROS 1	
490	CA145	RQ PCR based assay for MRD monitoring of Acute Leukaemia	
491	CA146	RQ-PCR BCR-ABL (P210)	
492	CA147	RQ-PCR PML-RARA	
493	CA148	RT-PCR Multiplex, Acute Leukaemia Panel	
494	CA149	RT-PCR Multiplex, BCR-ABL (P190, P210)	
495	CA150	RT-PCR Nested, IGH Chain Gene Rearrangement /TCR Gene Rearrangement	
496	CA151	Single Antigen Class I	
497	CA152	Single Antigen Class II	
498	CA153	Slide / Images for Second Opinion- Cancer Cytogenetics	
499	CA154	STR Panel studies	
500	CA155	Surface Marker Complete Panel	
501	CA156	Surface Marker Individual	
502	CA157	t(1;22) and Trisomy 21 in Acute Megakaryoblastic Leukemia (AML -M7) (2 Markers)	

503	CA158	T-cell Acute Lymphoblastic Leukemia (T-ALL) Panel	
504	CA159	TCR-A rearrangement: 14q11	
505	CA160	TERT Promoter Mutation Assay	
506	CA161	TFE-3 FISH	
507	CA162	TPMT (Thiopurine Methyl Transferase) Genotyping	
508	CA163	Trisomy 12	
509	CA164	Trisomy 21	
510	CA165	Trisomy 4, 10 & 17	
511	CA166	Trisomy 8	
512	CA167	V Beta Repertoire Analysis by Flow Cytometry for T-Cell Clonality	
513	CA168	XX/XY (Chimerism Studies) in Sex mismatch Bone Marrow Transplantation (BMT)	
514	CI001	Electrocardiogram (ECG)	

Note: Kindly provide the consent in the compliance column by writing Yes/NO and upload the complete list in technical bid. The condition of minimum coverage of CGHS test will be calculated based on this sheet.

Signature of the Bidder

Name : _____

Designation : _____

Annexure-VI
(In Reference to DTA Empanelment Tender of IIT Delhi)

List of Non-CGHS Tests

Srl	Test Name	MRP
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		

Note:

1. Add the number of rows/pages as required to cover all major non-CGHS test carried out by bidder in its own laboratory.
2. Kindly do not quote/mention discount rate for any of the tests on this sheet. The flat discount for the test mentioned by bidder on this sheet has to be provided in Sheet-2 of BoQ i.e. financial bid.

Signature of the Bidder

Name : _____

Designation : _____

Organization : _____

Contact No. : _____

Format for Financial Bid

BOQ Sheet 1

A	B	M	BA	BI
1	<div style="display: flex; justify-content: space-between; align-items: center;"> <div> <div style="border: 1px solid black; padding: 2px 5px; margin: 2px;">Validate</div> <div style="border: 1px solid black; padding: 2px 5px; margin: 2px;">Print</div> <div style="border: 1px solid black; padding: 2px 5px; margin: 2px;">Help</div> </div> <div style="text-align: right; color: red; font-weight: bold;">Item Rate BoQ</div> </div>			
4	Tender Inviting Authority: Indian Institute of Technology Delhi			
5	Name of Work: EMPANELMENT OF DIAGNOSTIC TESTING AGENCY (DTA)			
6	Contract No: IITD/KHOS(SP-5232)/2026			
8	<div style="display: flex;"> <div style="width: 15%; border: 1px solid black; padding: 2px;">Name of the Bidder/ Bidding Firm /</div> <div style="width: 85%; background-color: #e0ffff; border: 1px solid black;"></div> </div>			
9	PRICE SCHEDULE (This BOQ template must not be modified/replaced by the bidder and the same should be uploaded after filling the relevent columns, else the bidder is liable to be rejected for this tender. Bidders are allowed to enter the Bidder Name and Values only)			
10	NUMBER #	TEXT #	NUMBER #	NUMBER #
11	Sl. No.	Item Description	Overall discount offered on and above CGHS Rates (in %) only	Overall discount offered on and above CGHS Rates (in %) only
12	1	2	13	53
13	1	Overall discount offered on and above CGHS Rates		0.00
17				
18				
19				
20				
21				
22				

BOQ Sheet 2

<u>Item Rate BoQ</u>			
Tender Inviting Authority: Indian Institute of Technology Delhi			
Name of Work: EMPANELMENT OF DIAGNOSTIC TESTING AGENCY (DTA)			
Contract No: IITD/KHOS(SP-5232)/2026			
Name of the Bidder/ Bidding Firm /			
<u>PRICE SCHEDULE</u>			
(This BOQ template must not be modified/replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this tender. Bidders are allowed to enter the Bidder Name and Values only)			
NUMBER #	TEXT #	NUMBER #	NUMBER #
Sl. No.	Item Description	Discount on NON CGHS Tests (in %) only	Discount on NON CGHS Tests (in %) only
1	2	13	53
1	Overall discount offered on List of Non-CGHS tests as defined by the bidder in Annexure-V		0.00

BID SUBMISSION

Online Bid Submission:

The Online bids (complete in all respect) must be uploaded online in **two** Envelops as explained below: -

Envelope – 1			
(Following documents to be provided as single PDF file)			
Sl. No.	Document	Content	File Types
1.	Technical Bid	Compliance Sheet with Technical Supporting documents of all claims made at Compliance Sheet. (Annexure - I)	.PDF
2.		Basic Details (Annexure-II)	.PDF
3.		List of Govt. Organization/Deptt. At Annexure-III	.PDF
4.		DECLARATION SHEET (Annexure - IV)	.PDF
5.		List of CGHSTests Compliance (Annexure – V)	.PDF
6.		List of Non-CGHS Test (Annexure-VI)	.PDF
Envelope – 2			
Sl. No.	Document	Content	
1.	Financial Bid (Annexure – VII & VIII)	Price bid should be submitted in given BOQ_XXXX.xls format. (Note: -Comparison of prices will be done ONLY on the bids submitted for the Main Equipment and anything asked as ‘Optional’ in the specs is not to be included for overall comparison.) Bids for optional items are to be submitted in ‘sheet2_Quote for optional items’	.XLS